宜明昂科生物医药技术（上海）股份有限公司（股票代码：01541）于2026年6月12日发布翌日披露报表，报告显示该公司在香港联交所场内回购普通股2,600股。此次回购股份占2026年6月11日公司现有已发行股本（不含库存股）约0.0006%，每股回购价介乎3.35港元至3.36港元，总投入金额约8,722港元。
回购完成后，公司已发行股本（不含库存股）为419,717,105股，库存股数增至760,200股。该公司于2026年5月28日获股东大会授权回购最多43,150,769股，迄今已合计回购760,200股，占授权当日公司已发行股本（不含库存股）的0.1762%。
公司同时确认其回购行为符合香港联交所证券上市规则及相关法律与监管规定。公告由执行董事、联席公司秘书关梅签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.